Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
2 hedge funds and large institutions have $267K invested in Aratana Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 100 closing their positions.
98% less funds holding
Funds holding: 103 → 2 (-101)
100% less capital invested
Capital invested by funds: $193M → $267K (-$193M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 100
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$37.5M |
| 2 |
BlackRock
New York
|
-$19.3M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$16.4M |
| 4 |
Man Group
London,
United Kingdom
|
-$14.1M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$12.4M |
PETX Hedge Fund Activity: Q3 2019 in Review
2 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2019, worth a combined $267K — down 100% from $193M a quarter earlier.
Sellers outnumbered buyers: 100 funds closed out of PETX and 0 opened new positions — a net loss of 100 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Broadfin Capital, exiting entirely with an estimated $37.5M sold.
- 2 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2019, down from 103 in Q2 2019.
- Funds reported $267K of Aratana Therapeutics, Inc. stock for Q3 2019, down 100% quarter-over-quarter.
- 0 funds opened new Aratana Therapeutics, Inc. positions in Q3 2019 and 100 closed out, a net change of -100 holders.
- The largest Aratana Therapeutics, Inc. seller in Q3 2019 was Broadfin Capital, an estimated $37.5M sold.
Based on aggregated 13F filings for Q3 2019.